About: Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. The company was incorporated in 2005 and is based in Rosebery, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.16 (+23.08%)
VBSASXVectus Biosystems Ltd
Loading watchlist status…
Vectus Biosystems Ltd share price
VBS price activity
Last Price
Change (24hr)
AUD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
VBS price performance
0%
5D
-20%
1M
-11.11%
YTD
153.97%
1Y
VBS price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
AU-ASX rank
N/ASector Rank
N/AVBS Market Signals